This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
Is a Beat in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
by Zacks Equity Research
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
by Zacks Equity Research
Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.
Company News For Apr 9, 2018
by Zacks Equity Research
Companies in the news are: PSMT,CPB,BWEN,PCRX
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Heron's Pain Candidate Meets Endpoint in Pivotal Studies
by Zacks Equity Research
Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.
Pacira (PCRX) Posts Earnings in Q4, Revenues in Line
by Zacks Equity Research
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
Implied Volatility Surging for Pacira (PCRX) Stock Options
by Zacks Equity Research
Pacira (PCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira (PCRX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee
by Zacks Equity Research
Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira Focuses on Lead Candidate Exparel's Label Expansion
by Zacks Equity Research
We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.
Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Earnings Season Could Be Great for Pacira Pharmaceuticals (PCRX)
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc. (PCRX) may be one such company.
Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.
Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.